| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.LFS.2003.07.019 |
| P698 | PubMed publication ID | 14659973 |
| P2093 | author name string | Ken Ikeda | |
| Seiji Kobayashi | |||
| Keiji Miyata | |||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 843-853 | |
| P577 | publication date | 2004-01-01 | |
| P1433 | published in | Life Sciences | Q5256275 |
| P1476 | title | Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilization study in monkey cells | |
| P478 | volume | 74 |
| Q38860110 | Acetylcholinesterase Inhibitors and Drugs Acting on Muscarinic Receptors- Potential Crosstalk of Cholinergic Mechanisms During Pharmacological Treatment |
| Q51817526 | Antimuscarinic drugs for the treatment of female urinary incontinence. |
| Q40216123 | Clinical Impact of Solifenacin on Generic and Symptom-Specific Quality of Life for Females with Overactive Bladder: Using the Overactive Bladder Symptom Score and Rand Medical Outcomes Study 36-Item Health Survey |
| Q35419834 | Comparative Evaluation of the Safety and Efficacy of Long-Term Use of Imidafenacin and Solifenacin in Patients with Overactive Bladder: A Prospective, Open, Randomized, Parallel-Group Trial (the LIST Study) |
| Q36166331 | Improving the tolerability of anticholinergic agents in the treatment of overactive bladder |
| Q48024273 | Long-term prospective study of the persistence of solifenacin succinate in previously untreated Japanese female patients with overactive bladder |
| Q42142992 | Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice |
| Q35907276 | Preview of new drugs for overactive bladder and incontinence: darifenacin, solifenacin, trospium, and duloxetine |
| Q48475293 | Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes |
| Q34563524 | Solifenacin in overactive bladder syndrome |
| Q82442161 | Solifenacin in overactive bladder syndrome |
| Q36655193 | Solifenacin provides effective antimuscarinic therapy for the complete management of overactive bladder |
| Q30445725 | Solifenacin significantly improves all symptoms of overactive bladder syndrome |
| Q36608356 | Solifenacin. |
| Q38177369 | Solifenacin: pharmacology and clinical efficacy |
| Q36407417 | The emergence of new drugs for overactive bladder |
| Q36428471 | The overactive bladder: review of current pharmacotherapy in adults. Part 1: pathophysiology and anticholinergic therapy |
| Q42962559 | Urodynamic effects of solifenacin in untreated female patients with symptomatic overactive bladder |
Search more.